Mitochondrial genetics

Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction

Retrieved on: 
Friday, July 9, 2021

The waiver for Ms. Johnson will take effect on July 13, 2021 and the shares may be sold on or after such date.

Key Points: 
  • The waiver for Ms. Johnson will take effect on July 13, 2021 and the shares may be sold on or after such date.
  • Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP).
  • Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
  • REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.

Reneo Pharmaceuticals to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Retrieved on: 
Wednesday, July 7, 2021

SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it will provide a corporate update and participate in one-on-one investor meetings at the Ladenburg Thalmann 2021 Healthcare Conference, to be held virtually on July 13-14, 2021.

Key Points: 
  • SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it will provide a corporate update and participate in one-on-one investor meetings at the Ladenburg Thalmann 2021 Healthcare Conference, to be held virtually on July 13-14, 2021.
  • Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP).
  • Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
  • REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.

 Precision BioSciences Announces New Study Published in Nature Communications Using Engineered ARCUS Nuclease to Target Mutant Mitochondrial DNA In Vivo

Retrieved on: 
Tuesday, June 1, 2021

Additionally, both mutant and wild-type mtDNA can co-exist within the mitochondria of a cell, a phenomenon called mtDNA heteroplasmy.

Key Points: 
  • Additionally, both mutant and wild-type mtDNA can co-exist within the mitochondria of a cell, a phenomenon called mtDNA heteroplasmy.
  • When specific threshold levels of mutant mtDNA are reached, cell function can be compromised, and disease can manifest1.
  • In this study, a mitochondrial-targeted ARCUS nuclease (mitoARCUS) used to edit mutant mtDNA was particularly effective, in part because of the nucleases small size and single protein nature.
  • Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its wholly proprietary ARCUS genome editing platform.

Mitochondrial DNA Analysis Is Added to OmniTier’s CompStor® Family of Genomics Secondary and Tertiary Analysis Appliances

Retrieved on: 
Monday, March 1, 2021

OmniTier announced today that its CompStor family now supports mitochondrial analysis in both its secondary and tertiary analysis appliances.

Key Points: 
  • OmniTier announced today that its CompStor family now supports mitochondrial analysis in both its secondary and tertiary analysis appliances.
  • Variant calling on the mitochondrial genome must overcome additional challenges that are not present in standard nuclear genome analysis.
  • Because mitochondrial DNA is circular, standard linear analysis produces errors at the ostensible extremities of the mitochondrial sequence.
  • In addition, the number of types of mitochondrial DNA that may be present in a single sample is not simply bounded.

Minovia Therapeutics to Participate at Upcoming Credit Suisse Healthcare Conference on November 12th

Retrieved on: 
Monday, November 9, 2020

Minovia Therapeutics is a clinical stage company and the first to use a cell therapy approach to treat people affected with mitochondrial diseases through its Mitochondrial Augmentation Therapy (MAT) platform.

Key Points: 
  • Minovia Therapeutics is a clinical stage company and the first to use a cell therapy approach to treat people affected with mitochondrial diseases through its Mitochondrial Augmentation Therapy (MAT) platform.
  • MAT is being developed as a robust and scalable therapeutic platform targeting the root cause of diseases generated by mitochondrial dysfunction.
  • MAT enriches patients hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source.
  • Minovia is now conducting an IND enabled phase I/II clinical trial in Pearson Syndrome, a fatal pediatric disease.

Yuva Biosciences Scientific Founder Publishes COVID-19 Research In The American Journal Of Physiology

Retrieved on: 
Tuesday, August 25, 2020

Dr. Singh is the article's lead author and is the Scientific Founder of Yuva Biosciences.

Key Points: 
  • Dr. Singh is the article's lead author and is the Scientific Founder of Yuva Biosciences.
  • They also discuss how age-related progressive decline in mitochondrial function can result in increased susceptibility to COVID-19 morbidity and mortality in older individuals.
  • Yuva Biosciences is developing multiple approaches to enhance and restore mitochondrial function, initially targeting the hair and skin where loss of mitochondrial function results in hair loss and skin wrinkles.
  • The Company's Scientific Founder and Chief Scientific Advisor, Keshav K. Singh, Ph.D., is a world leader in the field of mitochondrial biology and genetics and its role in health, disease, and aging.

Khondrion announces first patients dosed in Phase IIb study of Sonlicromanol for mitochondrial diseases

Retrieved on: 
Monday, January 27, 2020

NIJMEGEN, the Netherlands Monday January 27, 2020: Khondrion, a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that the first patients have been successfully dosed in its phase IIb KHENERGYZE study of Sonlicromanol (previously known as KH176), its wholly-owned lead asset in development to treat a range of mitochondrial diseases.

Key Points: 
  • NIJMEGEN, the Netherlands Monday January 27, 2020: Khondrion, a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that the first patients have been successfully dosed in its phase IIb KHENERGYZE study of Sonlicromanol (previously known as KH176), its wholly-owned lead asset in development to treat a range of mitochondrial diseases.
  • The double-blind, randomised, placebo-controlled three-way cross-over study examining cognitive function will recruit patients with a specific genetically confirmed DNA mutation in the mitochondrial transfer RNALeu(UUR) (MT-TL1m.3243A>G).
  • Prof. Dr. Jan Smeitink, Chief Executive Officer at Khondrion, said: "The start of our phase IIb trial is another significant milestone for Khondrion as we aim to bring this important treatment to patients suffering from these devastating mitochondrial diseases.
  • Active discovery programmes are underway developing new therapies, biomarkers and new read-out technologies in the field of mitochondrial diseases.

Mitochondrial Disease Therapies Market, 2019-2030

Retrieved on: 
Wednesday, October 16, 2019

DUBLIN, Oct. 16, 2019 /PRNewswire/ -- The "Mitochondrial Disease Therapies Market, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 16, 2019 /PRNewswire/ -- The "Mitochondrial Disease Therapies Market, 2019-2030" report has been added to ResearchAndMarkets.com's offering.
  • The Mitochondrial Disease Therapies Market, 2019-2030 report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of therapeutics designed to treat mitochondrial diseases.
  • The chapter lays emphasis on genetic diseases caused due to mutations in the mitochondrial DNA and clinical conditions that are associated with mitochondrial dysfunction.
  • Chapter 10 features a detailed market forecast analysis, highlighting the likely growth of mitochondrial disease therapies till the year 2030.

Global Mitochondrial Disease Therapies Market (2019-2030) - Analysis of Key Industry Leaders

Retrieved on: 
Monday, October 14, 2019

Dublin, Oct. 14, 2019 (GLOBE NEWSWIRE) -- The "Mitochondrial Disease Therapies Market, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • Dublin, Oct. 14, 2019 (GLOBE NEWSWIRE) -- The "Mitochondrial Disease Therapies Market, 2019-2030" report has been added to ResearchAndMarkets.com's offering.
  • The Mitochondrial Disease Therapies Market, 2019-2030 report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of therapeutics designed to treat mitochondrial diseases.
  • An analysis of close to 200 peer-reviewed, scientific articles published during the period 2014-2019 (till February), highlighting the research focus within this niche industry segment.
  • One of the key objectives of the report was to estimate the existing market size and the future opportunity of therapies for mitochondrial diseases, over the next decade.

Mitochondrial Disease Therapies Market 2019, with Forecasts to 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 11, 2019

The "Mitochondrial Disease Therapies Market, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Mitochondrial Disease Therapies Market, 2019-2030" report has been added to ResearchAndMarkets.com's offering.
  • It is worth highlighting that over 300 mutations have been identified and are associated with various mitochondrial diseases.
  • It is also estimated that 1,000-4,000 children are born with a mitochondrial disease every year, in the same region.
  • The Mitochondrial Disease Therapies Market, 2019-2030 report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of therapeutics designed to treat mitochondrial diseases.